<VariationArchive VariationID="870642" VariationName="NG_008150.2:g.(27473_34849)_(43363_46929)dup" VariationType="Duplication" Accession="VCV000870642" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2020-05-12" MostRecentSubmission="2020-05-12">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="858813" VariationID="870642">
      <GeneList>
        <Gene Symbol="CHEK2" FullName="checkpoint kinase 2" GeneID="11200" HGNC_ID="HGNC:16627" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>22q12.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="28687743" stop="28741834" display_start="28687743" display_stop="28741834" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="29083730" stop="29137821" display_start="29083730" display_stop="29137821" Strand="-" />
          </Location>
          <OMIM>604373</OMIM>
          <Haploinsufficiency last_evaluated="2020-01-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CHEK2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-01-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CHEK2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NG_008150.2:g.(27473_34849)_(43363_46929)dup</Name>
      <VariantType>Duplication</VariantType>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_302" sequenceAccession="LRG_302">
            <Expression>LRG_302:g.(27473_34849)_(43363_46929)dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008150.2" sequenceAccession="NG_008150" sequenceVersion="2" change="g.(27473_34849)_(43363_46929)dup">
            <Expression>NG_008150.2:g.(27473_34849)_(43363_46929)dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NG_008150.2:g.(27473_34849)_(43363_46929)dup AND Familial cancer of breast" Accession="RCV001090197" Version="4">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-05-12" MostRecentSubmission="2020-05-12">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2467184" SubmissionDate="2019-08-06" DateLastUpdated="2020-05-12" DateCreated="2020-05-12">
        <ClinVarSubmissionID localKey="H" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001245494" DateUpdated="2020-05-12" DateCreated="2020-05-12" Type="SCV" Version="1" SubmitterName="Liquid Biopsy and Cancer Interception Group, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research" OrgID="507109" OrganizationCategory="laboratory" OrgAbbreviation="LB&amp;CI (L5)" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Caucasian</Ethnicity>
              <GeographicOrigin>Western Europe</GeographicOrigin>
              <Tissue>peripheral blood</Tissue>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">40</Age>
              <Age Type="maximum" age_unit="years">49</Age>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
              <FamilyData>
                <FamilyHistory>yes</FamilyHistory>
              </FamilyData>
              <Proband>yes</Proband>
            </Sample>
            <Method>
              <NamePlatform>MiSeq</NamePlatform>
              <TypePlatform>next-gen</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <TraitSet DateLastEvaluated="2019-07-15" Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <Name>
                  <ElementValue Type="Preferred">Invasive ductal carcinoma, grade 2, luminal A</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Caucasian</Ethnicity>
              <GeographicOrigin>Western Europe</GeographicOrigin>
              <Tissue>peripheral blood</Tissue>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">40</Age>
              <Age Type="maximum" age_unit="years">49</Age>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
              <FamilyData>
                <FamilyHistory>yes</FamilyHistory>
              </FamilyData>
              <Proband>yes</Proband>
            </Sample>
            <Method>
              <NamePlatform>MiSeq</NamePlatform>
              <TypePlatform>next-gen</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <TraitSet DateLastEvaluated="2019-07-15" Type="Finding">
              <Trait ClinicalFeaturesAffectedStatus="present" Type="Finding">
                <Name>
                  <ElementValue Type="Preferred">Invasive ductal carcinoma, grade 2, luminal A</ElementValue>
                </Name>
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CHEK2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NG_008150.2:g.(27473_34849)_(43363_46929)dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6135852</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2467184" TraitType="Finding" MappingType="Name" MappingValue="Invasive ductal carcinoma, grade 2, luminal A" MappingRef="Preferred">
        <MedGen CUI="None" Name="Invasive ductal carcinoma, grade 2, luminal A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2467184" TraitType="Finding" MappingType="Name" MappingValue="Invasive ductal carcinoma, grade 2, luminal A" MappingRef="Preferred">
        <MedGen CUI="None" Name="Invasive ductal carcinoma, grade 2, luminal A" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2467184" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

